Market expert Sudip Bandyopadhyay emphasizes the importance of strategic investments in the current economic climate. He views the recent selloff of State Bank of India as a profit-booking move rather than a reflection of its health, citing a 16% credit growth and a 3% net interest margin as indicators of stability. Bandyopadhyay believes the Indian pharma sector is entering a multi-decade growth phase, particularly following Sun Pharma's acquisition of Organon, which enhances its branded product portfolio. In contrast, he urges caution in the consumer sector, primarily due to potential risks from the El Niño-related monsoon, suggesting a focus on large-cap FMCG companies like HUL and Nestle. He expresses strong conviction in capital goods, advising investors to seize opportunities during price dips in quality stocks such as L&T, BHEL, and Thermax. For the IT sector, he recommends a selective approach, focusing on companies like HCL Technologies and Coforge, while waiting for more favorable valuation conditions.